- Home
- PDM vs FTRE Comparison
PDM vs FTRE Comparison
Compare PDM & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDM | FTRE |
|---|---|---|
| Founded | 1997 | 1996 |
| Country | United States | United States |
| Employees | 140 | N/A |
| Industry | Building operators | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1997 | 2023 |
Fundamental Metrics
Financial Performance| Metric | PDM | FTRE |
|---|---|---|
| Price | $9.58 | $17.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $9.00 | ★ $14.06 |
| AVG Volume (30 Days) | 966.9K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $564,994,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $4.21 | N/A |
| Revenue Next Year | $1.29 | $3.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $6.32 | $8.31 |
| 52 Week High | $10.13 | $21.39 |
Technical Indicators
Market Signals| Indicator | PDM | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 45.05 | 39.49 |
| Support Level | $9.41 | $16.45 |
| Resistance Level | $9.97 | $18.13 |
| Average True Range (ATR) | 0.22 | 0.77 |
| MACD | -0.03 | -0.19 |
| Stochastic Oscillator | 10.74 | 23.97 |
Price Performance
Historical ComparisonAbout PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.